# A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

> **NCT04325763** · PHASE3 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 315 (estimated)

## Conditions studied

- Stage III Non-small-cell Lung Cancer

## Interventions

- **DRUG:** TQB2450
- **DRUG:** Anlotinib
- **DRUG:** TQB2450(blank)
- **DRUG:** Anlotinib(blank)

## Key facts

- **NCT ID:** NCT04325763
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05-27
- **Primary completion:** 2022-12
- **Final completion:** 2025-03
- **Target enrollment:** 315 (ESTIMATED)
- **Last updated:** 2022-03-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04325763

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04325763, "A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04325763. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*